Article
Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
BMC cancer - 1 Sept 2020
Arrieta Oscar, Catalán Rodrigo, Guzmán-Vazquez Silvia, Barrón Feliciano, Lara-Mejía Luis, Soto-Molina Herman, Ramos-Ramírez Maritza, Flores-Estrada Diana, de la Garza Jaime
Abstract excerpt
BACKGROUND: Tyrosine-kinase inhibitors (TKIs) have become the cornerstone treatment of patients with non-small cell lung cancer that harbor oncogenic EGFR mutations. The counterpart of these drugs is the financial burden that they impose, which often creates a barrier for accessing treatment in developing countries. The aim if the present study was to compare the cost-effectiveness of three different first and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.